Glycotope Presents Phase I Results of Novel Glycooptimized Monoclonal anti-TA-MUC1 Antibody PankoMab-GEXTM at European Cancer Congress
Glycotope GmbH, a global leader in optimising the glycosylation of biopharmaceuticals and carbohydrate-specific antibodies (GlycoBodies), is presenting first-in-human results of their Phase I study of PankoMab-GEX, a glycoengineered antibody against their novel TA-MUC1 epitope, which is tumour-specific and abundantly present on many solid cancers, at this year's European Cancer Congress (ECCO 17). The annual congress is taking place from 27 September to 1 October in Amsterdam. Glycotope participated with a poster presentation in the session "Drug Development" on Sunday 29 September 2013.
Eligible patients with TA-MUC1 positive advanced solid tumours, progressing after standard treatments, were enrolled into this Phase I trial. Primary endpoints were safety and tolerability. Pharmacokinetics, immunogenicity and anti-tumour activity were also assessed.
PankoMab-GEXTM clearly demonstrated clinical activity as single agent in heavily pre-treated patients with far advanced cancers and could be safely administered at all tested doses and schedules with a very favorable safety, side effect and pharmacokinetic profile.
Related News
-
News Novartis signs US$3.2 bn subcutaneous delivery deal with Alteogen
Swiss pharma giant secures access to Korean biotech's ALT-B4 hyaluronidase platform in milestone-heavy agreement, marking Alteogen's fourth major licensing deal of 2026 as competition intensifies in the subcutaneous drug delivery space.
-
News Women in Pharma: The philosophy of pharmaceutical leadership
In this latest instalment of our Women in Pharma series, we sit down with Clarissa Sowemimo-Coker, Chief Strategy Officer at Ambrose Healthcare and CPHI Middle East Advisory Board Member.
-
News The PSCI Supplier Partnership - Collaboration for Responsible Supply Chains
About the Pharmaceutical Supply Chain Initiative The Pharmaceutical Supply Chain Initiative (PSCI) is the leading, member-led association for pharmaceutical companies working collaboratively to build responsible supply chains. Founded in 2006 and es... -
News AstraZeneca shares plunge 8.9% after reports of BMS talks
Britain's largest drugmaker lost more than GBP£17 billion in market value following reports of preliminary merger discussions with Bristol Myers Squibb that could create a pharmaceutical giant worth nearly US$400 billion, though investors rem... -
News GSK announces £400 million investment in new Cambridge R&D centre
Pharmaceutical giant to establish flagship research facility on Cambridge Biomedical Campus as part of strategic pipeline acceleration
-
News The CPHI Sustainability Summit - Where Conversation Becomes Collaboration
The Report Was Never the Destination - “The future of pharmaceutical sustainability won’t be shaped by individual organisations working in isolation. It will be shaped by partnerships, shared expertise and the willingness to work diffe... -
News Trump's generic drug tariffs set to reshape global pharmaceutical supply chains
The US president has announced plans to impose tariffs of up to 200% on imported generic medicines from August 2028, giving manufacturers a two-year window to establish domestic production facilities. The move threatens to upend a global supply chain t... -
News Building Safer, More Responsible Pharmaceutical Supply Chains: PSCI Global Audit Insights
The Pharmaceutical Supply Chain Initiative (PSCI) has released its seventh annual Audit Findings Analysis Report, offering unprecedented insights into supplier practices across the global pharmaceutical and healthcare industry.With a record-breaking 24...